Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Gilbert

Showing results (741-750 of 752) with videos related to

Pageof 76
Sort By:
Proceedings of the National Academy of Sciences of the United States of America|February 9, 2013
Animals in a bacterial world, a new imperative for the life sciencesMargaret McFall-Ngai, Michael G Hadfield, Thomas C G Bosch, et al.
JAMA Network Open|September 25, 2024
Emerging SARS-CoV-2 Resistance After Antiviral TreatmentTrevor J Tamura, Manish C Choudhary, Rinki Deo, et al.
Medrxiv : the Preprint Server for Health Sciences|March 9, 2022
Vaccine Breakthrough Infection with the SARS-CoV-2 Delta or Omicron (BA.1) Variant Leads to Distinct Profiles of Neutralizing Antibody ResponsesMichael S Seaman, Mark J Siedner, Julie Boucau, et al.
JCI Insight|October 10, 2022
Vaccine breakthrough infection leads to distinct profiles of neutralizing antibody responses by SARS-CoV-2 variantMichael S Seaman, Mark J Siedner, Julie Boucau, et al.
Bioorganic & Medicinal Chemistry Letters|October 23, 2012
Development of macrocyclic inhibitors of HCV NS3/4A protease with cyclic constrained P2-P4 linkersMichael T Rudd, Charles J McIntyre, Joseph J Romano, et al.
Bioorganic & Medicinal Chemistry Letters|October 2, 2012
Development of potent macrocyclic inhibitors of genotype 3a HCV NS3/4A proteaseMichael T Rudd, John A McCauley, Joseph J Romano, et al.
Science Translational Medicine|January 24, 2024
SARS-CoV-2 viral clearance and evolution varies by type and severity of immunodeficiencyYijia Li, Manish C Choudhary, James Regan, et al.
Chemmedchem|March 12, 2015
P2-quinazolinones and bis-macrocycles as new templates for next-generation hepatitis C virus NS3/4a protease inhibitors: discovery of MK-2748 and MK-6325Michael T Rudd, John W Butcher, Kevin T Nguyen, et al.
Medrxiv : the Preprint Server for Health Sciences|August 14, 2023
SARS-CoV-2 Viral Clearance and Evolution Varies by Extent of ImmunodeficiencyYijia Li, Manish C Choudhary, James Regan, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Discovery of MK-5172, a Macrocyclic Hepatitis C Virus NS3/4a Protease InhibitorSteven Harper, John A McCauley, Michael T Rudd, et al.
Pageof 76

Showing results (741-750 of 752) with videos related to

Sort By:
Pageof 76
Proceedings of the National Academy of Sciences of the United States of America|February 9, 2013
Animals in a bacterial world, a new imperative for the life sciencesMargaret McFall-Ngai, Michael G Hadfield, Thomas C G Bosch, et al.
JAMA Network Open|September 25, 2024
Emerging SARS-CoV-2 Resistance After Antiviral TreatmentTrevor J Tamura, Manish C Choudhary, Rinki Deo, et al.
Medrxiv : the Preprint Server for Health Sciences|March 9, 2022
Vaccine Breakthrough Infection with the SARS-CoV-2 Delta or Omicron (BA.1) Variant Leads to Distinct Profiles of Neutralizing Antibody ResponsesMichael S Seaman, Mark J Siedner, Julie Boucau, et al.
JCI Insight|October 10, 2022
Vaccine breakthrough infection leads to distinct profiles of neutralizing antibody responses by SARS-CoV-2 variantMichael S Seaman, Mark J Siedner, Julie Boucau, et al.
Bioorganic & Medicinal Chemistry Letters|October 23, 2012
Development of macrocyclic inhibitors of HCV NS3/4A protease with cyclic constrained P2-P4 linkersMichael T Rudd, Charles J McIntyre, Joseph J Romano, et al.
Bioorganic & Medicinal Chemistry Letters|October 2, 2012
Development of potent macrocyclic inhibitors of genotype 3a HCV NS3/4A proteaseMichael T Rudd, John A McCauley, Joseph J Romano, et al.
Science Translational Medicine|January 24, 2024
SARS-CoV-2 viral clearance and evolution varies by type and severity of immunodeficiencyYijia Li, Manish C Choudhary, James Regan, et al.
Chemmedchem|March 12, 2015
P2-quinazolinones and bis-macrocycles as new templates for next-generation hepatitis C virus NS3/4a protease inhibitors: discovery of MK-2748 and MK-6325Michael T Rudd, John W Butcher, Kevin T Nguyen, et al.
Medrxiv : the Preprint Server for Health Sciences|August 14, 2023
SARS-CoV-2 Viral Clearance and Evolution Varies by Extent of ImmunodeficiencyYijia Li, Manish C Choudhary, James Regan, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Discovery of MK-5172, a Macrocyclic Hepatitis C Virus NS3/4a Protease InhibitorSteven Harper, John A McCauley, Michael T Rudd, et al.
Pageof 76